Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

127.80USD
18 Jul 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$127.80
Open
$128.81
Day's High
$129.05
Day's Low
$127.17
Volume
7,152,355
Avg. Vol
6,787,616
52-wk High
$148.32
52-wk Low
$118.62

Chart for

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $357,562.41
Shares Outstanding(Mil.): 2,684.00
Dividend: 0.84
Yield (%): 2.52

Financials

  JNJ Industry Sector
P/E (TTM): 22.53 30.93 32.76
EPS (TTM): 5.91 -- --
ROI: 13.49 15.07 14.61
ROE: 22.63 16.60 16.34

Abbott Labs raises 2018 earnings forecast, shares hit record high

Abbott Laboratories raised its full-year earnings forecast and topped estimates for quarterly profit on Wednesday, powered by demand for its glucose monitoring device for diabetics and gains from its multibillion dollar acquisitions.

Jul 18 2018

UPDATE 2-Abbott Labs raises 2018 earnings forecast, shares hit record high

* Shares hit record high (Adds details from conference call, analysts' quotes, updates shares)

Jul 18 2018

GLOBAL MARKETS-Dollar firms after Fed chair's upbeat remarks, stocks gain

* Oil steadies on U.S. stockpile forecasts, Venezuela worries (Updates with close of U.S. trading)

Jul 17 2018

GLOBAL MARKETS-Dollar strengthens after Fed chair remarks, stocks higher

* Powell: "Several years" of strong jobs, low inflation ahead

Jul 17 2018

J&J beats quarterly expectations on drug sales surge, shares jump

Johnson & Johnson on Tuesday reported better-than-expected second quarter profit as sales of pharmaceuticals surged 20 percent despite a sharp decline in blockbuster arthritis drug Remicade, and its shares rose more than 4 percent.

Jul 17 2018

UPDATE 4-J&J beats quarterly expectations on drug sales surge, shares jump

* Pharma unit sales rise 20 pct, driven by cancer drug growth

Jul 17 2018

US STOCKS-J&J, Powell comment push Wall St higher; Netflix weighs

* Indexes up: Dow 0.07 pct, S&P 0.21 pct, Nasdaq 0.18 pct (Changes comment, adds details; updates prices)

Jul 17 2018

Tuesday Morning Briefing

For all the news you need to start your day, subscribe to the News Now newsletter. The best of Reuters news delivered right into your inbox absolutely free.

Jul 17 2018

Johnson & Johnson's quarterly profit rises 3.3 pct

July 17 Johnson & Johnson reported a 3.3 percent rise in quarterly profit on Tuesday, as higher sales of cancer drugs Zytiga and Darzalex helped offset pressure on its blockbuster rheumatoid arthritis treatment Remicade.

Jul 17 2018

J&J vows to overturn $4.7 billion talc verdict but experts see hurdles

NEW YORK Johnson & Johnson has vowed to appeal a $4.7 billion verdict awarded to 22 women who claim asbestos-contaminated talc in the company's products gave them ovarian cancer by arguing the plaintiffs' science was flawed and the case should not have been heard in Missouri. | Video

Jul 13 2018

Earnings vs. Estimates